Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 2/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5380556 | 0.90 | SMN1; SMN2 (0.48) | PTGS1PTGS2SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL4833608 | 0.84 | GAA (0.49) | KMT2APTGS1PTGS2SMN1; SMN2RAB9A | |
| SCHEMBL4833619 | 0.84 | GAA (0.49) | KMT2APTGS1PTGS2SMN1; SMN2RAB9A | |
| SCHEMBL4833310 | 0.80 | KMT2A (0.41) | KMT2APTGS1PTGS2SMN1; SMN2RAB9A | |
| SCHEMBL27632002 | 0.78 | ALDH1A1 (0.48) | PTGS1PTGS2RAB9AALDH1A1HTT | |
| SCHEMBL8886674 | 0.78 | NPBWR1 (0.55) | KMT2ASMN1; SMN2ALDH1A1HTTCYP11B1 | |
| SCHEMBL6429798 | 0.74 | MMP1 (0.46) | KMT2ASMN1; SMN2RAB9ANPC1POLB | |
| SCHEMBL6596242 | 0.73 | GAA (0.57) | KMT2APTGS1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL6596244 | 0.73 | GAA (0.57) | KMT2APTGS1SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL4825762 | 0.73 | KMT2A (0.77) | KMT2APTGS2SMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287438-A1 | Agent for preventing or treating neuropathy | MOMOSE YU | 2008-11-20 | — | — | US | disclosed |
| US-7423159-B2 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-09 | — | — | US | disclosed |
| CN-1731994-A | Prophylactic and therapeutic agent for neuropathy | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-08 | — | — | CN | disclosed |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1556032-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | Takeda Pharmaceutical Company Limited (JP) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004039365-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004069-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | KMT2A 1653/4885PTGS1 1761/4885PTGS2 414/4885 |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | KMT2A 1653/4885PTGS1 1761/4885PTGS2 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.